Texas’s AUSTIN— Pattern Bioscience, Inc., a pioneer in the field of bacterial diseases’ fast diagnosis and antibiotic susceptibility testing (AST), announced the successful conclusion of a USD 28.7 million Series C fundraising. The Antimicrobial Resistance Action Fund, Daleshaw Ltd., and Omnimed Capital participated in the most recent fundraising round, which Illumina Ventures and Omnimed Capital organized. The company has now received USD 68 million in total capital as a result of this new round.

To quickly develop effective treatments for drug-resistant bacterial infections, Pattern is a leader in the application of single-cell microbiology. With the additional funding, the business plans to finish creating its ground-breaking rapid phenotypic test platform for infectious diseases, conduct clinical validation studies, and submit the platform and its initial pneumonia test for FDA regulatory review.

Instead of the days needed for culture-based tests, the current standard, Pattern’s novel technology, based on single-cell analysis of microorganisms combined with machine learning, can generate clinically actionable data identifying the causal pathogen and profiling its antibiotic susceptibility in hours. The FDA granted the company’s first test, which will be conducted on hospitalized pneumonia patients, Breakthrough Device Designation, in December 2021. Future versions of Pattern’s technology will offer many additional tests.

Nick Arab, co-founder, and CEO of Pattern Bioscience, said, “We appreciate the support from our investors as we try to revolutionize bacterial testing with our single-cell microbiology platform. “We think that our technology will have a significant positive effect on patient outcomes and contribute to addressing the growing problem of antibiotic resistance.”

Drug-resistant bacterial infections claim over 1.3 million lives annually, costing the healthcare system billions of dollars. Faster diagnostic methods are urgently required to assist in addressing this epidemic by enabling tailored antibiotic therapy. It can take up to four days to obtain a conclusive diagnosis for a severely ill patient using standard-of-care culture-based diagnostics.  

The mission of Pattern Bioscience is to alter the diagnosis of bacterial illnesses to save lives and to lessen the burden of antibiotic resistance to advance global health. The company’s single-cell microbiology technology is the first and only rapid phenotypic testing platform to deliver clinically useful results promptly, allowing healthcare teams to provide patients with appropriate, life-saving treatments quickly enough to significantly alter outcomes. As opposed to the days needed for conventional culture testing, the company’s initial tests will be for critically ill patients with pneumonia and bacteremia, identifying the causative bacteria and its antibiotic susceptibility profile. Austin, Texas-based Pattern Bioscience is a privately held business that diagnostic industry veterans run with extensive expertise in delivering.

We try our  best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by! 

Next Article

Previous articleCalifornia-based lens tech startup Imagia raises USD 4.5 million in seed funding
Next articleSydney-based music licensing startup Melodie raises USD 1 million in funding at valuation of USD 15 million
Kshitij does business research and content writing for VCBay. Pursuing BBA from Symbiosis Center Of Management Studies (SCMS) Pune, he is skilled in Financial Modeling, Stock valuation and Microsoft Excel. He is passionate about Entrepreneurship and Finance.

LEAVE A REPLY

Please enter your comment!
Please enter your name here